COGT
Cogent Biosciences Inc
30.90$
-0.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -11.8% | +51.9% | -9.7% | -10.7% | -14.6% | -13.4% | -3.2% | +55.0% | +120.1% | -3.7% | -7.6% | |
| – | -5.3% | +63.2% | -16.3% | -7.7% | -13.2% | -14.7% | -3.1% | +62.1% | +129.2% | -3.6% | -8.3% | |
| – | -38.7% | +305.4% | -59.1% | +10.0% | +1.2% | +28.4% | +1.3% | -1.8% | +149.0% | -22.7% | -24.9% | |
| – | -4.8% | +64.0% | -16.6% | -7.6% | -14.4% | -14.4% | -3.2% | +64.3% | +130.4% | -3.8% | -8.6% | |
| – | +5.9% | -3.3% | +5.5% | +22.3% | +3.3% | -9.5% | +84.8% | +3.1% | +144.0% | -2.0% | +2.3% | |
| – | +9.9% | -3.9% | +9.0% | +32.6% | +5.0% | -11.5% | +18.5% | +6.5% | +2.7% | -9.3% | +2.3% | |
| – | +3.1% | +3.3% | +3.0% | +3.1% | +3.0% | +2.9% | +2.9% | +2.9% | -9.3% | -10.6% | +7.7% | |
| – | +8.0% | +46.1% | -42.3% | +67.8% | -20.2% | +17.8% | +17.5% | -3.6% | -40.7% | +44.6% | -45.5% | |
| – | – | – | – | – | – | – | – | +0.7% | +403.7% | +0.1% | +0.1% | |
| – | -14.9% | +63.8% | -11.6% | -15.7% | -18.6% | -14.6% | -29.2% | +95.1% | +110.4% | -4.5% | -12.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.7% | +9.3% | +4.7% | +11.0% | +0.3% | +3.1% | +0.1% | +22.7% | +15.1% | +6.1% | +0.1% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.